Completed PHASE3 INTERVENTIONAL 1-arm NCT00538915

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)

Sponsor: ADMA Biologics, Inc.

Conditions Primary Immune Deficiency Disorders (PIDD)

Interventions Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Updated 10 times since 2017 Last updated: Jul 28, 2021 Started: Sep 30, 2007 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Immune Deficiency Disorders (PIDD), this trial is completed. The trial is conducted by ADMA Biologics, Inc. and has accumulated 10 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Sep 2021 — Dec 2022 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ADMA Biologics, Inc.

Data source: ADMA Biologics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bellingham, United States , Birmingham, United States , Buffalo, United States , Centennial, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Hazard, United States , Irving, United States , Los Angeles, United States and 6 more locations